Monte Rosa Therapeutics Inc (NASDAQ: GLUE) is 27.79% higher on its value in year-to-date trading and has touched a low of $3.21 and a high of $12.40 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The GLUE stock was last observed hovering at around $7.05 in the last trading session, with the day’s gains setting it 0.17%.
Currently trading at $7.22, the stock is -13.92% and -10.57% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.73 million and changing 2.41% at the moment leaves the stock 21.54% off its SMA200. GLUE registered 28.47% gain for a year compared to 6-month gain of 113.61%. The firm has a 50-day simple moving average (SMA 50) of $8.0314 and a 200-day simple moving average (SMA200) of $5.934925.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -14.66% loss in the last 1 month and extending the period to 3 months gives it a 34.70%, and is 2.70% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.86% over the week and 9.93% over the month.
Monte Rosa Therapeutics Inc (GLUE) has around 133 employees, a market worth around $443.57M and $14.97M in sales. Profit margin for the company is -797.26%. Distance from 52-week low is 124.92% and -41.77% from its 52-week high. The company has generated returns on investments over the last 12 months (-48.63%).
The EPS is expected to grow by 61.74% this year
121.0 institutions hold shares in Monte Rosa Therapeutics Inc (GLUE), with institutional investors hold 91.25% of the company’s shares. The shares outstanding are 61.38M, and float is at 46.20M with Short Float at 18.19%. Institutions hold 90.60% of the Float.
The top institutional shareholder in the company is NEA MANAGEMENT COMPANY, LLC with over 7.69 million shares valued at $28.77 million. The investor’s holdings represent 12.7872 of the GLUE Shares outstanding. As of 2024-06-30, the second largest holder is PRICE T ROWE ASSOCIATES INC /MD/ with 5.98 million shares valued at $22.36 million to account for 9.9368 of the shares outstanding. The other top investors are FMR LLC which holds 5.09 million shares representing 8.4696 and valued at over $19.06 million, while BAKER BROS. ADVISORS LP holds 8.1722 of the shares totaling 4.92 million with a market value of $18.39 million.
Monte Rosa Therapeutics Inc (GLUE) Insider Activity
The most recent transaction is an insider sale by Versant Venture Capital VI, L., the company’s 10% Owner. SEC filings show that Versant Venture Capital VI, L. sold 89,990 shares of the company’s common stock on Oct 28 ’24 at a price of $9.66 per share for a total of $0.87 million. Following the sale, the insider now owns 2.01 million shares.
Monte Rosa Therapeutics Inc disclosed in a document filed with the SEC on Oct 29 ’24 that Versant Venture Capital VI, L. (10% Owner) sold a total of 67,905 shares of the company’s common stock. The trade occurred on Oct 29 ’24 and was made at $9.16 per share for $0.62 million. Following the transaction, the insider now directly holds 1.57 million shares of the GLUE stock.
Still, SEC filings show that on Oct 28 ’24, Wallace Owen B. (Officer) Proposed Sale 20,000 shares at an average price of $12.00 for $0.24 million. The insider now directly holds shares of Monte Rosa Therapeutics Inc (GLUE).
